MREO Stock Overview
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Mereo BioPharma Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.72 |
| 52 Week High | US$5.02 |
| 52 Week Low | US$1.86 |
| Beta | 0.97 |
| 11 Month Change | -12.68% |
| 3 Month Change | -23.61% |
| 1 Year Change | 73.02% |
| 33 Year Change | 95.79% |
| 5 Year Change | 56.96% |
| Change since IPO | -42.77% |
Recent News & Updates
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Shareholder Returns
| MREO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.4% | 2.5% | 2.2% |
| 1Y | 73.0% | 16.1% | 31.6% |
Return vs Industry: MREO exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: MREO exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| MREO volatility | |
|---|---|
| MREO Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MREO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MREO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Mereo BioPharma Group plc Fundamentals Summary
| MREO fundamental statistics | |
|---|---|
| Market cap | US$576.22m |
| Earnings (TTM) | -US$45.32m |
| Revenue (TTM) | US$1.00m |
576.2x
P/S Ratio-12.7x
P/E RatioIs MREO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MREO income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | -US$273.00k |
| Gross Profit | US$1.27m |
| Other Expenses | US$46.59m |
| Earnings | -US$45.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 127.30% |
| Net Profit Margin | -4,531.60% |
| Debt/Equity Ratio | 7.7% |
How did MREO perform over the long term?
See historical performance and comparison